Tauns Laboratories, Inc. (JP:197A) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
TAUNS Laboratories, Inc. has signed a license agreement with First Screening Corp. to utilize its electrochemical detection technology for expanding into cardiovascular, renal, and infectious disease testing. This move aligns with TAUNS’ strategy to diversify its offerings beyond respiratory infections, potentially increasing its corporate value through innovative, minimally invasive testing solutions. The collaboration is expected to accelerate product development and enhance TAUNS’ market presence across various healthcare settings.
For further insights into JP:197A stock, check out TipRanks’ Stock Analysis page.